As a side note to the list in message #13986 on the Biotech Values board (#msg-7221666), it’s worth noting that no plasma-derived AT is centrally approved by the EU.
One would presume Atryn will be lower priced then plasma products in EU to 'show off' the manufacturing efficiencies of transgenics. Perhaps pricier in the US where there is virtually no plasma competition. I think it would be a big mistake to price Atryn non-competitively. With lower cost manufacturing and potential gains in off label use and the potential for furmulary substitution it just makes sense.
Market Data 
Markets 
AI
